Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: A first navigation unit of an apparatus in one example comprises a hybrid global positioning system (GPS)/inertial navigation system (INS) component. The hybrid GPS/INS component provides first GPS information and first INS information for the first navigation unit. The first navigation unit is configured to receive second GPS information and second INS information from a second navigation unit. The second navigation unit comprises a GPS component configured to determine a double-differenced GPS carrier phase measurement through employment of the first GPS information and the second GPS information. The first navigation unit comprises a relative Kalman filter configured to update an INS error estimate for an estimate of a relative position between the first and second navigation units based on the double-differenced GPS carrier phase measurement and the first and second INS information.

Abstract: A method for estimating a probability of failure of a least-squares ambiguity decorrelation adjustment (LAMBDA) method is provided. The LAMBDA method is used for estimation of double difference carrier phase integer ambiguity. A plurality of condition sets are selected. Each condition set comprises a probability of failure (Pboot-fail) for a boot-strap method of estimation of the double difference carrier phase integer ambiguity, a number of space vehicles (Nsv), and a ratio test tolerance for the LAMBDA method. A plurality of Monte Carlo simulations are run on the plurality of condition sets to obtain a plurality of result sets. Each result set comprises a probability of lambda fail (P?-fail) and a probability of lambda reject (P?-reject) for one condition set of the plurality of condition sets. A lookup table is created with the plurality of result sets. A value of P?-fail for given values of P?-reject, Pboot-fail, and Nsv is estimated through employment of the lookup table.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: A pumpless liquid cooling system for removing heat from heat-generating components or systems comprises a heat absorbing portion or cold plate, a heat dissipating portion or heat exchanger and at least one driving device. The heat absorbing portion and the heat dissipating portion are of unitary construction as a sealed container with working fluid inside. The driving device and the heat dissipating portion is co-axially aligned and attached or fastened together. The heat absorbing portion is configured to have at least one thermal contact surface and a plurality of liquid passage within. The heat dissipating portion is configured to have a heat-dissipating body with plurality of external fins and an internal cylindrical liquid passage communicating with those of the heat absorbing portion and having a running fitting impeller driven by the driving device via magnetic forces to circulate the liquid in the heat transfer loop.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.

Abstract: A method for establishing a hybrid voice session between a mobile device and a VoIP device is disclosed. A caller using a mobile device in a mobile network initiates a request for a voice session by clicking on a virtual identifier, e.g. an email address, provided for the callee in an address book on the caller's mobile device. If the callee is online, then the request is enabled. In one embodiment, the request is enabled by creating a call registration record using a mobile data network. In another embodiment, the request is enabled by having the caller interact with an IVR system. In yet another embodiment, a caller can interact with the IVR system from any type of telephone device. The callee is notified regarding the voice session, and if accepted, the hybrid voice session is established via a voice channel and a VoIP channel.

Abstract: A first navigation unit of an apparatus in one example comprises a hybrid global positioning system (GPS)/inertial navigation system (INS) component. The hybrid GPS/INS component provides first GPS information and first INS information for the first navigation unit. The first navigation unit is configured to receive second GPS information and second INS information from a second navigation unit. The second navigation unit comprises a GPS component configured to determine a double-differenced GPS carrier phase measurement through employment of the first GPS information and the second GPS information. The first navigation unit comprises a relative Kalman filter configured to update an INS error estimate for an estimate of a relative position between the first and second navigation units based on the double-differenced GPS carrier phase measurement and the first and second INS information.

Abstract: The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

Abstract: Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: A laser peening process for the densification of metal surfaces and sub-layers and for changing surface chemical activities provides retardation of the up-take and penetration of atoms and molecules, particularly Hydrogen, which improves the lifetime of such laser peened metals. Penetration of hydrogen into metals initiates an embrittlement that leaves the material susceptible to cracking.

Abstract: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to the diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.